1
40
4
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
March 2020 List
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
March 2020 List
URL Address
<a href="http://doi.org/10.1016/j.jpainsymman.2019.12.179" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.jpainsymman.2019.12.179</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Telemedicine: the Pediatric Palliative Perspective (FR476)
Publisher
An entity responsible for making the resource available
Journal of Pain and Symptom Management
Date
A point or period of time associated with an event in the lifecycle of the resource
2020
Subject
The topic of the resource
adult; aggression; California; child; clinical article; clinical assessment; conference abstract; Current Procedural Terminology; drug safety; female; human; laptop; logging; male; medicaid; nurse; palliative therapy; patient comfort; physical examination; telemedicine; vital sign; young adult
Creator
An entity primarily responsible for making the resource
Marc-Aurele K L; Kuelker A; Stevens V; Bower K A
Description
An account of the resource
Objectives: * Describe the logistics of using telemedicine through an outpatient Pediatric Palliative Clinic. * Describe the experience of using telemedicine from the perspective of the parent, nurse, and physician.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.jpainsymman.2019.12.179" target="_blank" rel="noreferrer noopener">10.1016/j.jpainsymman.2019.12.179</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
2020
Adult
Aggression
Bower K A
California
Child
Clinical Article
clinical assessment
conference abstract
Current Procedural Terminology
Drug Safety
Female
Human
Journal of Pain and Symptom Management
Kuelker A
laptop
logging
Male
Marc-Aurele K L
March 2020 List
Medicaid
Nurse
Palliative Therapy
Patient Comfort
physical examination
Stevens V
Telemedicine
vital sign
Young Adult
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
2019 Oncology List
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Oncology 2019 List
URL Address
<a href="http://doi.org/10.1080/08880018.2019.1630537" target="_blank" rel="noreferrer noopener">http://doi.org/10.1080/08880018.2019.1630537</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Medical marijuana use for pediatric oncology patients: single institution experience
Publisher
An entity responsible for making the resource available
Pediatric Hematology and Oncology.
Date
A point or period of time associated with an event in the lifecycle of the resource
2019
Subject
The topic of the resource
adolescent; adult; adverse drug reaction; anxiety; article; burn; cancer patient; cancer therapy; child; childhood cancer; clinical article; drug safety; drug therapy; female; human; male; medical cannabis; Medical marijuana; microcapsule; mood; nausea and vomiting; pain; palliative therapy; pediatric oncology; prescription; side effect; sleep; smoke; smoking; supportive care; throat; vaporization; young adult
Creator
An entity primarily responsible for making the resource
Ofir R; Bar-Sela G; Weyl Ben-Arush M; Postovsky S
Description
An account of the resource
Medical marijuana (MM) is widespread in many medical fields, including oncology, with limited use in pediatric oncology where research is scarce and often shows conflicting results. This research focuses on alleviating side effects of anticancer treatment as an integral part of supportive and palliative care of children with cancer. We report our experience with MM treatment in 50 children, adolescents, and young adults with different types of cancer during 2010-2017. The main indications for prescriptions were nausea and vomiting, decreased mood, disturbed sleep, and pain. The medication was supplied to 30 patients via oil drops (60%) and 11 via smoking (22%), followed by vaporization, capsules, or combinations of various routes. Positive effects were reported by verbal children and parents in 80% of cases. MM was generally well tolerated with few patients reporting toxicity, with the most common adverse reactions being burning in the throat and anxiety attacks in subjects who chose to smoke the product. We conclude that MM may serve as a potentially useful complementary therapy to conventional supportive treatment of children suffering from cancer at the end of life. Further research is needed on the safety and efficacy and the consequences of prolonged use in pediatric populations. Copyright © 2019, © 2019 Taylor & Francis Group, LLC.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1080/08880018.2019.1630537" target="_blank" rel="noreferrer noopener">10.1080/08880018.2019.1630537</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
2019
Adolescent
Adult
Adverse Drug Reaction
anxiety
Article
Bar-Sela G
burn
Cancer Patient
Cancer Therapy
Child
Childhood Cancer
Clinical Article
Drug Safety
Drug Therapy
Female
Human
Male
medical cannabis
Medical Marijuana
microcapsule
Mood
Nausea And Vomiting
Ofir R
Oncology 2019 List
Pain
Palliative Therapy
Pediatric Hematology and Oncology.
Pediatric Oncology
Postovsky S
prescription
Side Effect
Sleep
smoke
Smoking
Supportive Care
throat
vaporization
Weyl Ben-Arush M
Young Adult
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Oncology
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Oncology 2017 List
URL Address
<a href="http://doi.org/10.1016/j.rchipe.2015.10.006" target="_blank" rel="noreferrer">http://doi.org/10.1016/j.rchipe.2015.10.006</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Use of opioids in palliative care of children with advanced cancer
Publisher
An entity responsible for making the resource available
Revista Chilena De Pediatria
Date
A point or period of time associated with an event in the lifecycle of the resource
2016
Subject
The topic of the resource
Advanced Cancer; Childhood Cancer; Opiate/dt [drug Therapy]; Palliative Therapy; 52-26-6 (morphine); 57-27-2 (morphine); 8002-76-4 (opiate); 8008-60-4 (opiate); 53663-61-9 (opiate); Adjuvant; Analgesia; Article; Child; Constipation; Diagnosis; Drug Efficacy; Drug Safety; Female; Human; Major Clinical Study; Male; Medical Record; Morphine; Morphine/dt [drug Therapy]; Nonsteroid Antiinflammatory Agent; Nonsteroid Antiinflammatory Agent/dt [drug Therapy]; Pain/dt [drug Therapy]; Pain Intensity; Retrospective Study; School Child; Sedation; Visual Analog Scale
Creator
An entity primarily responsible for making the resource
Fernandez Urtubia B; Trevigno Bravo A; Rodriguez Zamora N; Palma Torres C; Cid Barria L
Description
An account of the resource
Introduction Despite advances in the treatment of cancer in paediatric patients, 15% of children die from the illness progression in Chile, and pain is the most significant symptom in advanced stages. Although the World Health Organization guidelines demonstrate that opioids are fundamental in pain management, there is still resistance to their use. The main objective of this article was to describe the experience in the use of opioids for pain management in paediatric patients with advanced cancer in palliative care (PC). Patients and method Retrospective study of patients admitted into the PC Program at the Hospital Roberto del Rio between 2002 and 2013. Analysis was carried out on demographic data; oncological diagnosis; pain intensity on admission and discharge, according to validated scales; use of non-steroidal anti-inflammatory drugs; weak opioids; strong opioids; adjuvants drugs; the presence of secondary effects resulting from the use of morphine, and the need for palliative sedation. Results Of the 99 medical records analysed, the median age was 8 years, 64.6% were male, and there was a similar distribution in three oncological diagnosis groups. Upon admission, 43.4% presented intense to severe pain, and upon discharge there were four patients, but with a maximum VAS score of 7 in only one case. Of the 66 patients taking strong opioids, 89% required less than 0.5 mg/kg/hr. Constipation was the most frequently observed secondary effect. Conclusions Two thirds of the patients studied required strong opioids, with which adequate pain management was achieved, with no serious complications observed. The use of opioids in this group of patients, following a protocol, is considered effective and safe. Copyright _ 2015 Sociedad Chilena de Pediatria. Published por Elsevier Espana.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.rchipe.2015.10.006" target="_blank" rel="noreferrer">10.1016/j.rchipe.2015.10.006</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
2016
52-26-6 (morphine)
53663-61-9 (opiate)
57-27-2 (morphine)
8002-76-4 (opiate)
8008-60-4 (opiate)
Adjuvant
Advanced Cancer
Analgesia
Article
Child
Childhood Cancer
Cid Barria L
Constipation
Diagnosis
Drug Efficacy
Drug Safety
Female
Fernandez Urtubia B
Human
Major Clinical Study
Male
Medical Record
Morphine
Morphine/dt [drug Therapy]
Nonsteroid Antiinflammatory Agent
Nonsteroid Antiinflammatory Agent/dt [drug Therapy]
Oncology 2017 List
Opiate/dt [drug Therapy]
Pain Intensity
Pain/dt [drug Therapy]
Palliative Therapy
Palma Torres C
Retrospective Study
Revista Chilena De Pediatria
Rodriguez Zamora N
School Child
Sedation
Trevigno Bravo A
Visual Analog Scale
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
September 2017 List
Notes
<p>Using Smart Source Parsing ( (no pagination), 2015. Article Number: CD010750. Date of Publication: Mar 2015</p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Pharmacological Interventions For Pain In Children And Adolescents With Life-limiting Conditions
Publisher
An entity responsible for making the resource available
Cochrane Database Of Systematic Reviews
Date
A point or period of time associated with an event in the lifecycle of the resource
2017
Subject
The topic of the resource
Drug Efficacy; Neuropathic Pain/dt [drug Therapy]; Nociceptive Pain/dt [drug Therapy]; 52-26-6 (morphine); 57-27-2 (morphine); 73-78-9 (lidocaine); 76-42-6 (oxycodone); 76-57-3 (codeine); 76-99-3 (methadone); 94-09-7 (benzocaine); 94-24-6 (tetracaine); 103-90-2 (paracetamol); 124-90-3 (oxycodone); 125-56-4 (methadone); 133-16-4 (chloroprocaine); 136-47-0 (tetracaine); 137-58-6 (lidocaine); 297-88-1 (methadone); 437-38-7 (fentanyl); 1095-90-5 (methadone); 1134-47-0 (baclofen); 1333-08-0 (benzocaine); 2180-92-9 (bupivacaine); 3858-89-7 (chloroprocaine); 15307-79-6 (diclofenac); 15307-86-5 (diclofenac); 15687-27-1 (ibuprofen); 18010-40-7 (bupivacaine); 23142-53-2 (methadone); 24847-67-4 (lidocaine); 31121-93-4 (ibuprofen); 38396-39-3 (bupivacaine); 40391-99-9 (pamidronic Acid); 52485-79-7 (buprenorphine); 53152-21-9 (buprenorphine); 55750-21-5 (bupivacaine); 56934-02-2 (lidocaine); 57248-88-1 (pamidronic Acid); 66376-36-1 (alendronic Acid); 74103-06-3 (ketorolac); 79261-49-7 (ibuprofen); 527688-20-6 (ibuprofen); Alendronic Acid/ct [clinical Trial]; Alendronic Acid/dt [drug Therapy]; Analgesia; Baclofen/ct [clinical Trial]; Baclofen/dt [drug Therapy]; Benzocaine/ct [clinical Trial]; Benzocaine/dt [drug Therapy]; Bupivacaine/ct [clinical Trial]; Bupivacaine/dt [drug Therapy]; Buprenorphine/ct [clinical Trial]; Buprenorphine/dt [drug Therapy]; Cerebral Palsy; Chloroprocaine/ct [clinical Trial]; Chloroprocaine/dt [drug Therapy]; Codeine/ct [clinical Trial]; Codeine/dt [drug Therapy]; Diclofenac/ct [clinical Trial]; Diclofenac/dt [drug Therapy]; Drug Clearance; Drug Safety; Fentanyl/ct [clinical Trial]; Fentanyl/dt [drug Therapy]; Functional Status; Human; Ibuprofen/ct [clinical Trial]; Ibuprofen/dt [drug Therapy]; Ketorolac/ct [clinical Trial]; Ketorolac/dt [drug Therapy]; Length Of Stay; Lidocaine/ct [clinical Trial]; Lidocaine/dt [drug Therapy]; Methadone/ct [clinical Trial]; Methadone/dt [drug Therapy]; Morphine/ct [clinical Trial]; Morphine/dt [drug Therapy]; Neuropathic Pain/dt [drug Therapy]; Nociceptive Pain/dt [drug Therapy]; Osteogenesis Imperfecta; Oxycodone/ct [clinical Trial]; Oxycodone/dt [drug Therapy]; Pain Intensity; Pain Severity; Pamidronic Acid/ct [clinical Trial]; Pamidronic Acid/dt [drug Therapy]; Paracetamol/ct [clinical Trial]; Paracetamol/dt [drug Therapy]; Priority Journal; Psychological Well-being; Quality Of Life; Randomized Controlled Trial (topic); Review; Risk Benefit Analysis; Tetracaine/ct [clinical Trial]; Tetracaine/dt [drug Therapy]; Treatment Outcome
Creator
An entity primarily responsible for making the resource
Beecham E; Candy B; Howard R; McCulloch R; Laddie J; Rees H; Vickerstaff V; Bluebond-Langner M; Jones L
Description
An account of the resource
Background: Pain is one of the most common symptoms in children and young people (CYP) with life-limiting conditions (LLCs) which include a wide range of diagnoses including cancer. The current literature indicates that pain is not well managed, however the evidence base to guide clinicians is limited. There is a clear need for evidence from a systematic review to inform prescribing. Objectives: To evaluate the evidence on the effectiveness of different pharmacological interventions used for pain in CYP with LLCs. Search methods: The following electronic databases were searched up to December 2014: CENTRAL (in the Cochrane Library), MEDLINE, EMBASE, PsycINFO and CINAHL. In addition, we searched conference proceedings and reference lists of included studies. For completeness, we also contacted experts in the field. No language restrictions were applied. Selection criteria: Randomised controlled trials (RCTs), quasi-randomised studies and other studies that included a clearly defined comparator group were included. The studies investigated pharmacological treatments for pain associated with LLCs in CYP. The treatment included those specifically developed to treat pain and those that acted as an adjuvant, where the treatment was not primarily developed to treat pain but has pain relieving properties. The LLC was identified by its inclusion in the Richard Hain Directory of LLCs. Data collection and analysis: Citations were screened by five review authors. Data were extracted by one review author and checked by a second. Two review authors assessed the risk of bias of included studies. A sufficient number of studies using homogeneous outcomes was not identified so a meta-analysis was not possible. Main results: We identified 24,704 citations from our database search. Nine trials with 379 participants fulfilled our inclusion criteria. Participants had cerebral palsy (CP) in five of the studies and osteogenesis imperfecta (OI) in the other four. Participants across the trials ranged in age from 2 to 19 years. All studies, apart from one cross-over trial, were parallel designed RCTs. Three of the trials on CP evaluated intrathecal baclofen (ITB) and two botulinum toxin A (BoNT-A). All of the OI trials evaluated the use of bisphosphonates (two alendronate and one pamidronate). No trials were identified that evaluated a commonly used analgesic in this patient group. Pain was a secondary outcome in five of the eight identified studies. Overall the quality of the trials was mixed. Only one study involved over 100 participants. For the two ITB studies for pain in CP, in the same study population but assessed at different time points in their disease, both found an effect on pain favouring the intervention compared to the control group (standard care or placebo) (mean difference (MD) 4.20, 95% confidence interval (CI) 2.15 to 6.25; MD 26.60, 95% CI 2.61 to 50.59, respectively). In these studies most of the adverse events related to the procedure or device for administration rather than the drug, such as swelling at the pump site. In one trial there were also eight serious adverse effects; these included difficulty swallowing and an epileptic seizure. The trial did not state if these occurred in the intervention group. At follow-up in both BoNT-A trials there was no evidence of a difference in pain between the trial arms among CP participants. The adverse events in the BoNT-A trials mostly involved those who received the intervention drug and involved seizures. Gastrointestinal problems were the most frequent adverse event in those who received alendronate. The trial investigating pamidronate found no evidence of a difference in pain compared to the control group. No adverse events were reported in this trial. Authors' conclusions: Published, controlled evidence on the pharmacological interventions for pain in CYP with LLCs is limited. The evidence that is currently available evaluated pain largely as a secondary outcome and the drugs used were all adjuvants and not always commonly used in general paediatric palliative care for p
Identifier
An unambiguous reference to the resource within a given context
10.1002/14651858.CD010750.pub2
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
103-90-2 (paracetamol)
1095-90-5 (methadone)
1134-47-0 (baclofen)
124-90-3 (oxycodone)
125-56-4 (methadone)
133-16-4 (chloroprocaine)
1333-08-0 (benzocaine)
136-47-0 (tetracaine)
137-58-6 (lidocaine)
15307-79-6 (diclofenac)
15307-86-5 (diclofenac)
15687-27-1 (ibuprofen)
18010-40-7 (bupivacaine)
2017
2180-92-9 (bupivacaine)
23142-53-2 (methadone)
24847-67-4 (lidocaine)
297-88-1 (methadone)
31121-93-4 (ibuprofen)
38396-39-3 (bupivacaine)
3858-89-7 (chloroprocaine)
40391-99-9 (pamidronic Acid)
437-38-7 (fentanyl)
52-26-6 (morphine)
52485-79-7 (buprenorphine)
527688-20-6 (ibuprofen)
53152-21-9 (buprenorphine)
55750-21-5 (bupivacaine)
56934-02-2 (lidocaine)
57-27-2 (morphine)
57248-88-1 (pamidronic Acid)
66376-36-1 (alendronic Acid)
73-78-9 (lidocaine)
74103-06-3 (ketorolac)
76-42-6 (oxycodone)
76-57-3 (codeine)
76-99-3 (methadone)
79261-49-7 (ibuprofen)
94-09-7 (benzocaine)
94-24-6 (tetracaine)
Alendronic Acid/ct [clinical Trial]
Alendronic Acid/dt [drug Therapy]
Analgesia
Baclofen/ct [clinical Trial]
Baclofen/dt [drug Therapy]
Beecham E
Benzocaine/ct [clinical Trial]
Benzocaine/dt [drug Therapy]
Bluebond-Langner M
Bupivacaine/ct [clinical Trial]
Bupivacaine/dt [drug Therapy]
Buprenorphine/ct [clinical Trial]
Buprenorphine/dt [drug Therapy]
Candy B
Cerebral Palsy
Chloroprocaine/ct [clinical Trial]
Chloroprocaine/dt [drug Therapy]
Cochrane Database of Systematic Reviews
Codeine/ct [clinical Trial]
Codeine/dt [drug Therapy]
Diclofenac/ct [clinical Trial]
Diclofenac/dt [drug Therapy]
Drug Clearance
Drug Efficacy
Drug Safety
Fentanyl/ct [clinical Trial]
Fentanyl/dt [drug Therapy]
Functional Status
Howard R
Human
Ibuprofen/ct [clinical Trial]
Ibuprofen/dt [drug Therapy]
Jones L
Ketorolac/ct [clinical Trial]
Ketorolac/dt [drug Therapy]
Laddie J
Length Of Stay
Lidocaine/ct [clinical Trial]
Lidocaine/dt [drug Therapy]
McCulloch R
Methadone/ct [clinical Trial]
Methadone/dt [drug Therapy]
Morphine/ct [clinical Trial]
Morphine/dt [drug Therapy]
Neuropathic Pain/dt [drug Therapy]
Nociceptive Pain/dt [drug Therapy]
Osteogenesis Imperfecta
Oxycodone/ct [clinical Trial]
Oxycodone/dt [drug Therapy]
Pain Intensity
Pain Severity
Pamidronic Acid/ct [clinical Trial]
Pamidronic Acid/dt [drug Therapy]
Paracetamol/ct [clinical Trial]
Paracetamol/dt [drug Therapy]
Priority Journal
Psychological Well-being
Quality Of Life
Randomized Controlled Trial (topic)
Rees H
Review
Risk Benefit Analysis
September 2017 List
Tetracaine/ct [clinical Trial]
Tetracaine/dt [drug Therapy]
Treatment Outcome
Vickerstaff V